Page 61 - Aneck News Today

With the Federal Reserve signalling multiple interest rate rises, writes Russel Chesler, what does this mean for value investing?

Pharmaceuticals stocks and the related exchange traded funds are benefiting from the now-steady revenue stream provided by coronavirus vaccines.

One benefit of a turbulent January for equities is that some stocks, including familiar names, are now trading at more attractive multiples.

Cryptocurrencies took another step toward widespread legitimacy as lawmakers in Wyoming and Arizona, put forward proposals.

The Federal Reserve is poised to raise interest rates, and that cycle could commence as soon as March.

Global markets are entering into a new regime in 2022, according to VanEck, as interest rate fears dominate and investors look for companies with an ability to protect their margins and earnings against inflation.

Interest rates are poised to rise, perhaps as soon as March. However, rates are coming off rock-bottom levels.

Semiconductor stocks and exchange traded funds aren't being spared as the broader technology sector struggles to start 2022.

The fallen angels index outperformed the broad high yield index by 0.40% in December and by 2.36% for 2021 (7.72% vs 5.36%).

The market believes that aggressive rate hikes in parts of EM will be followed by rate cuts later in 2022, as growth falters and disinflation kicks in.